Azenta, Inc.

Azenta, Inc. (AZTA) Stock Analysis

$34.090

-2.267 (-6.65%)At close

Loading chart…
High
37.170
Open
36.990
VWAP
34.76
Volume
1.26M
Mkt Cap
2.81B
Low
33.030
Amount
43.87M
EV/EBITDA, TTM
36.27

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software.

AI analysis of Azenta, Inc. (AZTA)

Hold

Azenta Inc is currently a hold. The stock is priced at $37.72, which is above the analyst price target of $35, indicating potential overvaluation. The recent RSI of 56.115 suggests that the stock is neither overbought nor oversold, but the negative sentiment from ongoing investigations into securities claims could pose risks.

Valuation Metrics

The current forward P/E ratio for Azenta, Inc. (AZTA) is 29.07, compared to its 5-year average forward P/E of 186.84.

Forward P/E

Fair
5Y Average P/E
186.84
Current P/E
29.07
Overvalued
487.64
Undervalued
-113.96

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
29.69
Current EV/EBITDA
36.27
Overvalued
68.04
Undervalued
-8.66

Forward P/S

Fair
5Y Average P/S
4.86
Current P/S
2.55
Overvalued
8.06
Undervalued
1.67

Alphio AI Price Scenarios for AZTA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%AZTA

$34.77

Scenario price

B

Base

Base · 50%AZTA

$30.40

Scenario price

B

Bear

Bear · 25%AZTA

$25.27

Scenario price

Whales holding AZTA

A

American Capital Management, Inc.

+ HoldingAZTA

+3.92%

3M Return

Events Timeline

2026-08-24 (ET)

08:30:00

Company Reaffirms Q4 Total Revenue Guidance

08:30:00

Azenta Appoints Martin Madaus as Interim CEO

2026-08-04 (ET)

17:00:00

Company Q3 Revenue Exceeds Expectations at $161M

17:00:00

Total Organic Revenue Expected to Decline in Q4 FY2025

17:00:00

Company Expects Organic Revenue Flat to Up 1% for FY2025

News

AZTA FAQ — answered by Alphio AI

Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Company develops solutions for automated ultra-cold storage. It operates through two segments, which include Sample Management Solutions and Multiomics. The Sample Management Solutions segment operates as a single business unit offering end-to-end sample management products and services, including sample repository services and core products (automated stores, cryogenic systems, automated sample tube, consumables and instruments and controlled rate thawing devices). The Multiomics segment operates as a single business unit offering genomic and other sample analysis services, including gene sequencing, gene synthesis and related services. It offers a portfolio of products and sample services including procurement, automated storage systems, genomic services and a multitude of sample consumables, informatics and data software. It operates in the Healthcare sector (SPECIAL INDUSTRY MACHINERY, NEC industry).

Azenta Inc is currently a hold. The stock is priced at $37.72, which is above the analyst price target of $35, indicating potential overvaluation. The recent RSI of 56.115 suggests that the stock is neither overbought nor oversold, but the negative sentiment from ongoing investigations into securities claims could pose risks.

Community

More ↗
Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading